Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Reaches New 1-Year Low – Here’s What Happened

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)’s stock price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $26.41 and last traded at $26.67, with a volume of 40673 shares. The stock had previously closed at $27.21.

Analyst Upgrades and Downgrades

LKFT has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, May 26th. Morgan Stanley assumed coverage on Lakefront Biotherapeutics American Depositary Shares in a report on Friday, July 10th. They set an “equal weight” rating and a $30.00 target price on the stock. Wall Street Zen cut Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Zacks Research upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $34.33.

Lakefront Biotherapeutics American Depositary Shares Trading Down 1.8%

The company has a market cap of $1.76 billion, a price-to-earnings ratio of -18.94 and a beta of 0.25. The firm’s fifty day moving average price is $28.81 and its 200-day moving average price is $30.41.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of ($1.27) by $1.52. The firm had revenue of $8.75 million during the quarter, compared to the consensus estimate of $11.26 million. As a group, research analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -10.83 EPS for the current year.

Institutional Investors Weigh In On Lakefront Biotherapeutics American Depositary Shares

Several large investors have recently modified their holdings of LKFT. Western Standard LLC bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the 4th quarter valued at about $1,046,000. UBS Group AG increased its stake in Lakefront Biotherapeutics American Depositary Shares by 128.4% during the 4th quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock worth $11,427,000 after purchasing an additional 196,445 shares in the last quarter. Man Group plc increased its stake in Lakefront Biotherapeutics American Depositary Shares by 31.5% during the 4th quarter. Man Group plc now owns 47,581 shares of the biotechnology company’s stock worth $1,556,000 after purchasing an additional 11,384 shares in the last quarter. XTX Topco Ltd raised its holdings in Lakefront Biotherapeutics American Depositary Shares by 92.6% during the 4th quarter. XTX Topco Ltd now owns 23,219 shares of the biotechnology company’s stock worth $759,000 after buying an additional 11,162 shares during the period. Finally, Aquatic Capital Management LLC raised its holdings in Lakefront Biotherapeutics American Depositary Shares by 63.6% during the 3rd quarter. Aquatic Capital Management LLC now owns 17,516 shares of the biotechnology company’s stock worth $607,000 after buying an additional 6,807 shares during the period. 32.46% of the stock is currently owned by institutional investors.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.